NCT07103655View on ClinicalTrials.gov

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

July 1, 2026

Study Completion Date

January 1, 2027

Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
DRUG

mavacamten

Add Mavacamten to guideline-directed standard medical therapy for patients with hypertrophic cardiomyopathy (HCM) and mid-to-apical left ventricular obstruction.

DRUG

Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol

Administer an appropriate dose of beta-blockers according to the patient's tolerance.

DRUG

diltiazem

Administer an appropriate dose of diltiazem according to the patient's tolerance.

Trial Locations (1)

310009

Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER